Navitoclax(ABT-263)单药治疗重度经治复发性上皮性卵巢癌女性的II期研究:MONAVI - GINECO研究
这项前瞻性多中心单臂II期研究评估了Navitoclax单药在46例重度经治(2-12线,中位4线)高级别浆液性铂耐药卵巢癌患者中的疗效,主要终点为基于RECIST v1.1的無进展生存期(PFS)。3个月PFS率为22.7%[95%CI: 13.2-39.2],中位PFS为1.64个月[95%CI: 1.58-2.30],总缓解(RECIST v1.1)16例(35.6%,95%CI: 22.3-51.3),包括1例部分缓解和15例疾病稳定。血小板减少是主要副作用(G3/4:n=12;26%),未观察到显著出血或毒性死亡。结论认为Navitoclax单药活性差,且与Bim、Mcl-1和P-ERK表达不相关,但毒性可接受。
要点
- Navitoclax单药在重度经治铂耐药卵巢癌中3个月PFS率22.7%,中位PFS 1.64个月。
- 总缓解16例(35.6%),其中1例部分缓解、15例疾病稳定。
- 血小板减少G3/4发生12例(26%),导致8例维持150 mg/d、3例停药。
核心结论
- Navitoclax单药活性差,且与Bim、Mcl-1和P-ERK表达不相关,但无不可接受的毒性。
研究设计与样本
- 前瞻性多中心单臂II期研究,纳入46例重度经治(2-12线,中位=4)高级别浆液性铂耐药卵巢肿瘤患者。
- Navitoclax给药方案:导入期(7-14天)每日150 mg,若无剂量限制性血小板减少(<G3)则增至每日250 mg。
- 主要终点为基于RECIST v1.1标准的无进展生存期(PFS);计划分析肿瘤活检中Bcl-2家族蛋白表达与疗效的关系。
主要发现
- 3个月PFS率为22.7%[95%CI: 13.2-39.2],中位PFS为1.64个月[95%CI: 1.58-2.30]。
- 总缓解(RECIST v1.1)16例(35.6%,95%CI: 22.3-51.3),包括1例部分缓解和15例疾病稳定。
- 本研究未发现Bim、Mcl-1和P-ERK表达与临床缓解之间存在相关性。
- 血小板减少是主要副作用(G3/4:n=12;26%),导致8例患者维持每日150 mg剂量,3例患者停止治疗。
- 未观察到显著出血或毒性死亡。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There are limited treatment options for ovarian cancer patients with early relapse after platinum chemotherapy. In preclinical studies, we previously demonstrated the promising activity of ABT-737, a Bcl-2/Bcl-xL anti-apoptotic protein inhibitor, in chemo-resistant ovarian cancer cells and tumors, suggesting its potential activity in platinum-resistant patients. METHODS: We conducted a prospective multicenter single-arm phase II study to assess the efficacy of Navitoclax (orally available ABT-737 analogue) monotherapy in 46 heavily pretreated (2-12 lines, median = 4) patients with high-grade serous platinum-resistant ovarian tumors. Navitoclax was administered at the daily dose of 150 mg during a lead-in period (7-14 days) and then increased to 250 mg daily in the absence of dose-limiting thrombocytopenia (<G3). Progression-free survival (PFS) based on RECIST v1.1 criteria was the primary endpoint. Analysis of efficacy according to the expression of Bcl-2 family proteins in tumor biopsies was also planned. RESULTS: The 3-month PFS was 22.7% [95%CI: 13.2-39.2], median PFS was 1.64 months [95%CI: 1.58-2.30]. There were 16 (35.6%, 95%CI: 22.3-51.3) overall responses (RECIST v1.1): 1 partial response and 15 stable diseases. No correlation between the expression of Bim, Mcl-1 and P-ERK with clinical response was found in this study. Thrombocytopenia was the major side-effect (G3/4: n = 12; 26%), leading to pursue at the daily dose of 150 mg in 8 patients and to discontinue treatment in 3 patients. Neither significant bleeding nor toxic death were observed. CONCLUSIONS: Navitoclax monotherapy had poor activity that was not correlated with the expression of Bim, Mcl-1 and P-ERK, without unacceptable toxicity. TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT02591095.
引用
- Joly F, Fabbro M, Follana P, et al. A phase II study of Navitoclax (ABT-263) as single agent in women heavily pretreated for recurrent epithelial ovarian cancer: The MONAVI - GINECO study. Gynecol Oncol. 2022. PMID: 35123771. doi:10.1016/j.ygyno.2022.01.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。